As their first clin­i­cal da­ta test looms, glob­al AI play­er In­sil­i­co bumps up a GSK vet to co-CEO in charge of de­vel­op­ment

Days af­ter top­ping up In­sil­i­co Med­i­cine’s cash re­serves with a $60 mil­lion round, the glob­al AI play­er is re­design­ing its ex­ec­u­tive struc­ture with an un­usu­al twist as it shifts from pure drug de­sign and dis­cov­ery and builds out the pipeline with clin­i­cal stage as­sets.

A lit­tle more than a year af­ter step­ping in as the CSO, Feng Ren, the Har­vard grad and GSK vet with ex­pe­ri­ence in Philadel­phia and Shang­hai, is step­ping up to a co-CEO role. He’ll be in charge of the de­vel­op­ment work, as they start test­ing more of their drugs in hu­mans and put their promise of a more ef­fi­cient ap­proach to drug hunt­ing to the ul­ti­mate test.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER